[Form 4] 10x Genomics, Inc. Insider Trading Activity
10x Genomics insider sale by CFO Adam Taich, the company's Chief Financial Officer and reporting person, reported a sale of 22,315 shares of Class A Common Stock on 08/22/2025 at a price of $13.787 per share. Following the sale, Mr. Taich beneficially owned 309,273 shares, reported as direct ownership. The filing explains the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Taich on 08/26/2025.
Vendita azionaria interna di 10x Genomics da parte del CFO Adam Taich, Chief Financial Officer e soggetto segnalante della societ脿, ha comunicato la vendita di 22.315 azioni di Class A Common Stock il 22/08/2025 al prezzo di $13,787 per azione. Dopo la vendita, il sig. Taich deteneva beneficiariamente 309.273 azioni, riportate come propriet脿 diretta. La comunicazione specifica che le azioni sono state vendute per coprire gli obblighi di ritenuta fiscale derivanti dalla maturazione di restricted stock units. Il Modulo 4 猫 stato firmato per procura a nome del sig. Taich il 26/08/2025.
Venta interna de 10x Genomics por parte del CFO Adam Taich, el Director Financiero y persona informante de la compa帽铆a, inform贸 la venta de 22.315 acciones de Class A Common Stock el 22/08/2025 a un precio de $13,787 por acci贸n. Tras la venta, el Sr. Taich pose铆a beneficiariamente 309.273 acciones, reportadas como propiedad directa. la presentaci贸n explica que las acciones se vendieron para cubrir obligaciones de retenci贸n fiscal derivadas del vencimiento de unidades de acciones restringidas. El Formulario 4 fue firmado por un apoderado en nombre del Sr. Taich el 26/08/2025.
10x Genomics 雮措秬鞛� 毵り皝 鈥� CFO 須岇偓鞚� 斓滉碃鞛毂呾瀯鞛愳澊鞛� 氤搓碃鞛�(氤搓碃雽�靸侅瀽)鞚� Adam Taich電� 2025雲� 8鞗� 22鞚�鞐� Class A 氤错喌欤� 22,315欤茧ゼ 欤茧嫻 $13.787鞐� 毵り皝頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 毵り皝 頉� Taich 鞌姅 歆侅爲 靻岇湢搿� 氤搓碃霅� 309,273欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�. 頃措嫻 鞝滌稖靹滊電� 欤检嫕鞚� Restricted Stock Units鞚� 甓岆Μ臧� 頇曥爼霅橂┐靹� 氚滌儩頃� 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╇嫻頃橁赴 鞙勴暣 毵り皝霅橃棃雼り碃 靹る獏頃╇媹雼�. 鞏戩嫕 4電� 2025雲� 8鞗� 26鞚� Taich 鞌ゼ 雽�鞁犿暅 氩曥爜 雽�毽澑(鞙勳瀯氚涭潃 氤�順胳偓)鞐� 鞚橅暣 靹滊獏霅橃棃鞀惦媹雼�.
Vente interne chez 10x Genomics par le CFO Adam Taich, directeur financier et personne d茅clarante de la soci茅t茅, a signal茅 la vente de 22 315 actions de Class A Common Stock le 22/08/2025 au prix de 13,787 $ par action. Apr猫s la vente, M. Taich d茅tenait effectivement 309 273 actions, d茅clar茅es comme propri茅t茅 directe. Le dossier explique que les actions ont 茅t茅 vendues pour couvrir les obligations de retenue d鈥檌mp么t r茅sultant de la lev茅e (vesting) d鈥檜nit茅s d鈥檃ctions restreintes. Le formulaire 4 a 茅t茅 sign茅 par un mandataire au nom de M. Taich le 26/08/2025.
Insider-Verkauf bei 10x Genomics durch den CFO Adam Taich, der Chief Financial Officer und meldepflichtige Person des Unternehmens, meldete den Verkauf von 22.315 Aktien der Class A Common Stock am 22.08.2025 zu einem Preis von $13,787 je Aktie. Nach dem Verkauf hielt Herr Taich wirtschaftlich 309.273 Aktien, angegeben als Direktbesitz. Die Meldung erkl盲rt, dass die Aktien verkauft wurden, um Steuerabzugsverpflichtungen infolge der Vesting-Phase von Restricted Stock Units zu decken. Das Formular 4 wurde am 26.08.2025 von einem Bevollm盲chtigten im Namen von Herrn Taich unterschrieben.
- Transparent disclosure of insider sale and remaining beneficial ownership
- Sale explicitly tied to tax withholding from RSU vesting, indicating routine administrative purpose
- None.
Insights
TL;DR CFO sold a modest number of shares to cover taxes from RSU vesting; remaining ownership still material.
The sale of 22,315 Class A shares at $13.787 was disclosed as a tax-withholding disposition tied to RSU vesting, not an open-market decision to reduce exposure. Post-transaction beneficial ownership of 309,273 shares remains sizeable for an officer and is reported as direct ownership. This Form 4 provides routine transparency required under Section 16; it does not disclose any change in employment, compensation policy, or new equity grants beyond the stated tax-related sale.
TL;DR Transaction appears procedural and customary for equity-based compensation tax withholding.
The explanation explicitly states the disposition was to satisfy tax withholding on vested restricted stock units, which is a common and permissible practice. The filing is properly executed by an attorney-in-fact, satisfying signature requirements. No indications of unusual timing, related-party transfers, or derivatives are present in the submission. As a governance disclosure, this Form 4 is routine and neutral in investor impact.
Vendita azionaria interna di 10x Genomics da parte del CFO Adam Taich, Chief Financial Officer e soggetto segnalante della societ脿, ha comunicato la vendita di 22.315 azioni di Class A Common Stock il 22/08/2025 al prezzo di $13,787 per azione. Dopo la vendita, il sig. Taich deteneva beneficiariamente 309.273 azioni, riportate come propriet脿 diretta. La comunicazione specifica che le azioni sono state vendute per coprire gli obblighi di ritenuta fiscale derivanti dalla maturazione di restricted stock units. Il Modulo 4 猫 stato firmato per procura a nome del sig. Taich il 26/08/2025.
Venta interna de 10x Genomics por parte del CFO Adam Taich, el Director Financiero y persona informante de la compa帽铆a, inform贸 la venta de 22.315 acciones de Class A Common Stock el 22/08/2025 a un precio de $13,787 por acci贸n. Tras la venta, el Sr. Taich pose铆a beneficiariamente 309.273 acciones, reportadas como propiedad directa. la presentaci贸n explica que las acciones se vendieron para cubrir obligaciones de retenci贸n fiscal derivadas del vencimiento de unidades de acciones restringidas. El Formulario 4 fue firmado por un apoderado en nombre del Sr. Taich el 26/08/2025.
10x Genomics 雮措秬鞛� 毵り皝 鈥� CFO 須岇偓鞚� 斓滉碃鞛毂呾瀯鞛愳澊鞛� 氤搓碃鞛�(氤搓碃雽�靸侅瀽)鞚� Adam Taich電� 2025雲� 8鞗� 22鞚�鞐� Class A 氤错喌欤� 22,315欤茧ゼ 欤茧嫻 $13.787鞐� 毵り皝頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 毵り皝 頉� Taich 鞌姅 歆侅爲 靻岇湢搿� 氤搓碃霅� 309,273欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�. 頃措嫻 鞝滌稖靹滊電� 欤检嫕鞚� Restricted Stock Units鞚� 甓岆Μ臧� 頇曥爼霅橂┐靹� 氚滌儩頃� 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╇嫻頃橁赴 鞙勴暣 毵り皝霅橃棃雼り碃 靹る獏頃╇媹雼�. 鞏戩嫕 4電� 2025雲� 8鞗� 26鞚� Taich 鞌ゼ 雽�鞁犿暅 氩曥爜 雽�毽澑(鞙勳瀯氚涭潃 氤�順胳偓)鞐� 鞚橅暣 靹滊獏霅橃棃鞀惦媹雼�.
Vente interne chez 10x Genomics par le CFO Adam Taich, directeur financier et personne d茅clarante de la soci茅t茅, a signal茅 la vente de 22 315 actions de Class A Common Stock le 22/08/2025 au prix de 13,787 $ par action. Apr猫s la vente, M. Taich d茅tenait effectivement 309 273 actions, d茅clar茅es comme propri茅t茅 directe. Le dossier explique que les actions ont 茅t茅 vendues pour couvrir les obligations de retenue d鈥檌mp么t r茅sultant de la lev茅e (vesting) d鈥檜nit茅s d鈥檃ctions restreintes. Le formulaire 4 a 茅t茅 sign茅 par un mandataire au nom de M. Taich le 26/08/2025.
Insider-Verkauf bei 10x Genomics durch den CFO Adam Taich, der Chief Financial Officer und meldepflichtige Person des Unternehmens, meldete den Verkauf von 22.315 Aktien der Class A Common Stock am 22.08.2025 zu einem Preis von $13,787 je Aktie. Nach dem Verkauf hielt Herr Taich wirtschaftlich 309.273 Aktien, angegeben als Direktbesitz. Die Meldung erkl盲rt, dass die Aktien verkauft wurden, um Steuerabzugsverpflichtungen infolge der Vesting-Phase von Restricted Stock Units zu decken. Das Formular 4 wurde am 26.08.2025 von einem Bevollm盲chtigten im Namen von Herrn Taich unterschrieben.
FAQ
What did Adam Taich (TXG) report on Form 4?
How many 10x Genomics (TXG) shares does the CFO own after the sale?
Why were the shares sold according to the filing?
Who signed the Form 4 for Adam Taich?
Does the Form 4 show any derivative transactions or new grants?
